BLASUBCUTANEOUSINJECTABLE
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GONAL-F RFF (follitropin alfa/beta) is a recombinant human follicle-stimulating hormone (FSH) administered via subcutaneous injection for fertility treatment. It is indicated for ovulation induction in women with anovulation or oligo-ovulation and for multifollicular development in assisted reproductive technology (ART) cycles. The drug directly stimulates follicular growth and maturation in the ovary.
LOE Approaching
As LOE approaches, the brand team is likely shifting focus to lifecycle management, patient retention, and cost-containment strategies rather than expansion initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GONAL-F RFF offers exposure to specialty pharma, managed care strategy, and fertility medicine, but career trajectory is characterized by LOE-phase dynamics focused on patient retention and cost management rather than growth. This role is best suited for professionals interested in deep therapeutic expertise in reproductive medicine and defending market position in the face of generic/biosimilar competition.
Brand Manager
Worked on GONAL-F RFF at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.